Connect with us

Technology

Landmark Blood-Based AI Lung Cancer Screening Test Study Results Published in Cancer Discovery

Published

2 years ago

on

The transformative approach to genomic sequencing yields the first validated high-sensitivity lung cancer screening test that could close gaps in screening.

BALTIMORE and PALO ALTO, Calif., June 3, 2024 /PRNewswire/ — DELFI Diagnostics, Inc., a developer of accessible blood-based AI tests that deliver a new way to enhance cancer detection, today announces the publication of groundbreaking data in the prestigious journal Cancer Discovery from the company’s L101 study, “Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection”. The report details the performance and potential of DELFI’s FirstLook Lung test. This milestone study, led by top researchers in the field, marks a significant advancement in aiding blood-based cancer detection.

FirstLook Lung is the first validated high-sensitivity test designed to close the persistent gap and shortfall observed in lung cancer screening. Lung cancer claims more lives of both men and women than any other cancer. Yet despite strong evidence from randomized trials that lung cancer screening is highly effective at reducing the burden and harms of this disease, only 5% of those eligible are screened each year according to the American Lung Association. Introducing a high-sensitivity blood-based lung cancer screening test with the validated performance of FirstLook Lung, the study authors project that even modest utilization could translate to thousands of prevented deaths from lung cancer.

Key Findings and Implications
The study, titled “Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection” involved 958 participants, divided into a group for test training, and a separate independent group for test validation. The authors detail the genomic elements derived through low-cost whole genome sequencing and show in the independent validation group that both sensitivity and specificity are remarkably consistent across patient subgroups that differ in demographics, comorbidities, and smoking history. They then present the potential population health impact of the test if used to augment lung cancer screening in the United States, showing that even modest utilization would translate into meaningful shifts toward early-stage diagnosis and downstream reductions in lung cancer deaths.

Key findings include:

Sensitivity: 80% in a screening population across stages of diseaseNegative Predictive Value (NPV): 99.8%, meaning a test result of “not elevated” equates to a 2 in 1,000 chance someone has lung cancerRelative Risk: The likelihood of lung cancer found by low dose computed tomography scan is 5.5 times higher for individuals with a FirstLook Lung “elevated” versus “not elevated” result.

L101 principal investigator, Peter J. Mazzone, M.D. noted that “To improve lung cancer screening outcomes at scale, a low-cost test with high sensitivity and high NPV is essential. The results of the validation show that DELFI’s test meets these criteria, and our models show the potential population health benefits achievable through even modest adoption. We are long overdue in our need to close lung cancer screening’s gaps.”

DELFI Chief Medical Officer, Peter B. Bach, M.D., commented: “This publication in Cancer Discovery is just our first step toward improving screening rates with a widely accessible test now available as a laboratory-developed test (LDT). We are making the test available to partners and customers who share our vision and are committed to improving screening rates across populations in need. We remain committed to additional prospective assessment of the test and platform under our breakthrough device designation with the FDA and in our international collaborations.”

DELFI Founder Victor Velculescu, M.D. PhD, commented: “Five years ago, we published a seminal study showing the insights available in the cancer fragmentome for noninvasive cancer detection. Seeing this translated into a high-performing test for early detection of lung cancer that can be accessible to all is what scientists dream about.”

About FirstLook Lung
FirstLook Lung evaluates patterns of DNA fragments in the blood that reveal the presence of lung cancer. In an independent validation, FirstLook Lung was shown to have 80% sensitivity in a screening population, including detection of the earliest stages of the disease. The test also demonstrated a negative predictive value (NPV) of 99.8 percent for determining if lung cancer would be discovered on a screening Chest CT. Early detection is key to improving patient outcomes.

About Lung Cancer
Lung cancer is the number one cause of cancer death globally and in the United States where it accounts for 25 percent of all cancer deaths – just as many deaths as the other four cancers for which screening is recommended combined (colon, prostate, breast, and cervical cancer). Screening rates for those other cancers are in the 60 to 70 percent range, but lung cancer screening with low-dose CT scans is received by only approximately six percent of screen-eligible adults in the U.S. annually. This means that 14.1 million Americans who should be getting screened every year for lung cancer are not doing so. According to the 2021 USPSTF lung cancer screening guidelines, individuals eligible for screening include those 50 to 80 years of age, and who currently smoke or have quit within the last 15 years and have a 20-pack year or more smoking history. Detecting cancer early can improve outcomes. The low rate of lung screening is an important reason why the disease’s five-year survival rate in the U.S. is only 23 percent.

About DELFI Diagnostics
DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals’ cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. To learn more about the FirstLook Lung test, visit www.delfidiagnostics.com or www.firstlooktest.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/landmark-blood-based-ai-lung-cancer-screening-test-study-results-published-in-cancer-discovery-302162028.html

SOURCE DELFI Diagnostics

Related Topics:
Continue Reading

Technology

commercetools Named a Leader in 2026 Gartner® Magic Quadrant™ for Digital Commerce as AI Reshapes the Market

Published

43 minutes ago

on

October 22, 2026

By

commercetools is a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Commerce for the seventh consecutive year.commercetools has been driving AI innovation on how enterprises build, operate and sell, including capabilities like Sphere, Commerce MCP and commercetools for Builders.commercetools is helping global enterprises modernize complex commerce operations and prepare for a future where both people and AI agents discover, shop and transact.

BOSTON, Oct. 22, 2026 /PRNewswire/ — commercetools, the digital commerce AI company, today announced it has been positioned as a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Commerce. This marks the seventh consecutive year commercetools has been recognized as a Leader in the report.

As AI reshapes commerce, commercetools is expanding how it supports the enterprises who build and operate commerce experiences, and the shoppers who use them. Global enterprises including JD Sports, Nederlandse Spoorwegen, Chemist Warehouse and Mirion Technologies are using commercetools to modernize complex digital commerce, accelerate growth and adopt new AI-powered ways of operating and selling.

“Commerce is moving from systems that simply respond to human instructions toward systems that can increasingly understand, decide and act,” said Doug McNary, Chief Executive Officer at commercetools. “We’re proud to be named a Leader for the seventh consecutive year. Enterprises shouldn’t have to choose between the flexibility they need today and the autonomy they’ll need tomorrow. Our focus is giving them the technology to support both.”

Over the past year, commercetools has introduced new products and capabilities designed to bring AI across the commerce lifecycle:

Sphere: Brings together commercetools’ AI-native infrastructure and agent governance through Commerce MCP into a unified platform for enterprises to build, operate and sell with AI.commercetools for Builders: Helps anyone build, extend and evolve enterprise commerce faster with AI.AgentSphere: Lets enterprises build and manage AI agents to run commerce operations and agentic shopping, with appropriate guardrails to do so safely and at scale.Modular commerce offerings: Gives enterprises the flexibility to start with the capabilities they need and expand over time, accelerating time to value without requiring a full commerce transformation upfront.Commerce Integration Layer: Centralizes integration logic behind customer-facing experiences. Storefronts, mobile apps and AI agents connect through a unified layer hosted and maintained by commercetools.Smart Data Modeler: Uses AI to accelerate product data modeling, helping teams build the right foundation faster and reduce time-to-launch.

commercetools’ customers include large enterprises across retail, manufacturing, life sciences, healthcare and telecommunications in markets around the world.

To learn more about commercetools’ position as a Leader, download your complimentary copy of the 2026 Gartner Magic Quadrant report today.

About the Gartner Magic Quadrant for Digital Commerce

Gartner, Magic Quadrant for Digital Commerce Platforms, Aditya Vasudevan, Penny Gillespie, Sandy Shen, Jason Daigler, Mike Lowndes, 19 October 2026

Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About commercetools

commercetools, the global digital commerce AI company, helps enterprises transform commerce for the AI era. Built API-native from the start and AI-first by design, our technology enables agentic shopping experiences, automates commerce operations and gives businesses the agility to modernize faster, innovate continuously and operate more intelligently.

More than 500 global brands, retailers and enterprise companies rely on commercetools to power their digital commerce. Together, they process more than $100 billion in annualized GMV, over 700 million orders and more than one billion customer records on our platform.

Media Contact: comms@commercetools.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/commercetools-named-a-leader-in-2026-gartner-magic-quadrant-for-digital-commerce-as-ai-reshapes-the-market-302916761.html

SOURCE commercetools

Continue Reading

Technology

Phylo’s Biomni Lab to expand the use of AI agents in scientific research at Bayer

Published

44 minutes ago

on

October 22, 2026

By

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 /PRNewswire/ — Phylo, Inc. announced today a partnership with Bayer to deploy Biomni Lab, Phylo’s agentic AI platform to accelerate scientific research and evaluation. 

Under the agreement, Phylo will provide Bayer with full access to its agentic platform that helps Bayer scientists bring together scientific literature, biomedical data, and analytical methods in one environment, reducing the manual effort required to assemble and assess evidence. The platform’s inspectable workflows preserve the context behind each result, allowing researchers to review the underlying sources, methods, and execution and apply their own scientific judgment. Bayer scientists will gain access to Biomni Lab for workflows focused on assembling literature and omics evidence for drug discovery.

“This partnership reflects our belief that AI should expand scientific curiosity, not just speed up routine work. Giving our scientists an AI partner that brings rigor to every step lets them explore more ideas, ask bolder questions, and find the insights that move drug discovery forward, ultimately accelerating the pace at which we can bring new medicines to patients,” said Sai Jasti, Senior Vice President, Head of Data Science & Artificial Intelligence, Bayer Pharmaceuticals R&D.

“For agentic AI to matter in research, it has to earn the trust of the scientists doing the work. Bayer’s selection of Biomni Lab is a strong endorsement of the scientific rigor and AI capabilities we’ve built into the platform,” said Kexin Huang, Ph.D., Co-Founder and CEO of Phylo. “Our vision is an AI-native operating system for biopharma, where every scientist can direct a team of AI agents to pursue complex research questions. With Bayer, we aim to show what becomes possible when AI capabilities meet deep scientific expertise: more hypotheses explored, more discoveries made, and new possibilities for medicine.”

About Phylo

Phylo’s mission is to bring the best agentic intelligence to every biomedical scientist. Its enterprise-grade AI platform, Biomni Lab, is the first Integrated Biology Environment—a unified workspace where scientists collaborate with AI agents across literature research, experimental design, biological data analysis, and scientific decision-making.

Biomni Lab is now used by leading global biopharma, including Bayer, Chugai Pharmaceutical and Ono Pharmaceutical. Phylo is based in South San Francisco, backed by Andreessen Horowitz (a16z) and Menlo Ventures.

For more information, visit phylo.bio. To learn more about Biomni Lab, visit biomni.phylo.bio.

View original content to download multimedia:https://www.prnewswire.com/news-releases/phylos-biomni-lab-to-expand-the-use-of-ai-agents-in-scientific-research-at-bayer-302917080.html

SOURCE Phylo, Inc.

Continue Reading

Technology

Sandler Partners Welcomes Bryan Rias as Director, Sales Engineer, West Region

Published

44 minutes ago

on

October 22, 2026

By

New Hire Announcement | Independent Technology Distributor Sandler Partners grows its Sales Engineering team, adding Bryan Rias as Director, Sales Engineer, West Region.

REDONDO BEACH, Calif., Oct. 22, 2026 /PRNewswire/ — Sandler Partners, the leading independent Technology Solutions Distributor, announces the addition of Bryan Rias as Director, Sales Engineer, West Region, further strengthening its dedicated sales engineering team and the technical support available to Partners in the West Region.

Bryan brings more than two decades of experience designing and delivering complex technology solutions, including enterprise and Cloud architecture roles at Lumen/Savvis and IBM focused on infrastructure modernization and customer success. His expertise spans automation, edge computing, disaster recovery, application performance monitoring (APM), and DevSecOps. In his role, Bryan will support Partners across the West Region, aligning early with them on strategy and leading thoughtful discovery to help them find the right fit for each client.

For Bryan, strong relationships and solid values guide his life and form the foundation of his professional success, a perspective that fits naturally within the Sandler Partners community. When he is not working, Bryan spends time with his family, including his wife, three sons, and a grandson, RVing, boating, and biking, along with pursuing his passion for freediving.

“Bryan brings the kind of hands-on experience our Partners value: he’s been in the room on complex deals and knows how to turn a customer’s needs into the right solution,” says Justin Marano, Chief Revenue Officer, Sandler Partners. “He came to Sandler for the freedom to work across best-of-breed Providers, and our Partners in the West will feel that right away. He’s collaborative, grounded, and focused on helping Partners win. I’m excited to have him on the team.”

“I’m excited to get to work alongside our Partners, helping them navigate complex opportunities and bring clarity to technical decisions,” says Bryan. “For me, it all comes back to relationships. When you build them on trust and shared values, the results follow for our Partners and their clients. That’s something that the Sandler community really embodies, and I look forward to getting to work with our Partners!”

About Sandler Partners
Sandler Partners helps empower its network of leading independent Sales Partners to deliver a comprehensive range of technology solutions to organizations worldwide, including Cybersecurity, Artificial Intelligence (AI), Connectivity, Cloud, Colocation, Mobility, Internet of Things (IoT), and Continuity. Its community-focused approach enables Partners to identify the right solutions for customers quickly and objectively from a diverse portfolio of 220+ Providers. Partner sales agents, VARs, and MSPs gain access to an innovative suite of sales tools within the Sandler Portal—including SCOUT, Solutions Finder, Scout for Solutions, and the Marketing Center—several of which are AI-powered, all backed by a robust support network, dedicated Sales Engineering expertise, and rich marketing resources. Together, these tools and resources empower Partners to focus on what they do best: delivering quality, value, performance, innovative solutions, unmatched expertise, and exceptional service to their clients. Members of the Sandler Partners community also benefit from the industry’s strongest negotiated agreements and a dedicated team committed to ensuring commissions are accurately identified, tracked, and paid. For more information, visit www.sandlerpartners.com.

Sandler Partners – Media Contact
Tina S. Dyksterhouse
tina@sandlerpartners.com
310-861-2295

View original content to download multimedia:https://www.prnewswire.com/news-releases/sandler-partners-welcomes-bryan-rias-as-director-sales-engineer-west-region-302916413.html

SOURCE Sandler Partners

Continue Reading

Trending